Add BrightSurf on Google Email

Johns Hopkins Medicine


Picking apart how neurons learn

Researchers identified two critical molecular events: PICK1's role in removing AMPA receptors and phosphorylation's effect on the receptor. These findings provide new understanding of long-term depression and its connection to motor learning, such as the vestibulo-ocular reflex.

SourceJohns Hopkins Medicine·JournalNeuron·DateMar 29, 2006

Junk DNA may not be so junky after all

Scientists have identified human enhancers able to control expression consistent with the zebrafish ret gene, shedding light on Hirschsprung disease and multiple endocrine neoplasia. The new system uses zebrafish to test mammalian DNA and is a significant advance over current methods.

SourceJohns Hopkins Medicine·JournalScience·DateMar 23, 2006

Johns Hopkins scientists exploit novel route to reverse enlarged hearts in obese mice

Researchers at Johns Hopkins Medicine discovered that injecting ciliary neurotrophic factor (CNTF) into obese mice with leptin deficiency or resistance reduced their heart muscle walls by up to a third and the size of the left ventricle by 41%. This breakthrough suggests a novel brain-signaling pathway for obesity-related heart failure.

SourceJohns Hopkins Medicine·JournalProceedings of the National Academy of Sciences·DateMar 6, 2006

Delayed prostate cancer surgery poses no increased risk for some patients

A new study by Johns Hopkins Medicine found that men with low-grade prostate cancer who receive active surveillance may not be at increased risk of noncurable prostate cancer. The study compared outcomes in men who delayed surgery for two years to those who underwent immediate treatment, finding no significant difference in risk.

SourceJohns Hopkins Medicine·JournalJNCI Journal of the National Cancer Institute·DateFeb 28, 2006

Low-level heat wrap therapy safely reduces low back pain and improves mobility in the workplace

Researchers found that using a low-level heat wrap therapy (CLHT) for three consecutive days significantly reduced pain intensity and improved pain relief, with benefits maintained in the follow-up period. The study showed CLHT to be a safe and effective alternative for treating acute low back pain.

SourceJohns Hopkins Medicine·JournalJournal of Occupational and Environmental Medicine·DateJan 19, 2006

Patient safety monitoring at Hopkins Hospital finds law of unintended consequences at work

A Hopkins investigation found that a newly introduced catheter valve was linked to a spike in bloodstream infections in the pediatric intensive care unit. The team identified mechanical issues with the device as the likely source of infection, highlighting the need for closer monitoring of technology's safety.

SourceJohns Hopkins Medicine·JournalInfection Control and Hospital Epidemiology·DateJan 9, 2006

New drug lets thyroid cancer patients avoid nasty side effects during treatment

Researchers have discovered a new treatment option for thyroid cancer that allows patients to continue their thyroid hormone replacement therapy while undergoing radioiodine treatment, reducing unpleasant side effects. This breakthrough could improve the overall quality of life for thyroid cancer patients during treatment.

SourceJohns Hopkins Medicine·JournalThe Journal of Clinical Endocrinology & Metabolism·DateJan 9, 2006

A little telomerase isn't enough

Researchers found that mice with half the normal amount of telomerase can't maintain their stem cells' chromosome ends, leading to early demise. The study suggests that inherited disease may be caused by inherited telomere length, not the status of the telomerase gene.

SourceJohns Hopkins Medicine·JournalCell·DateDec 22, 2005

Researchers reveals how certain chemicals protect the brain against cell damage

A recent study published in European Journal of Neuroscience reveals that prostaglandin E2 (PGE2) can provide protection against brain cell death by stimulating receptors EP2 and EP4. This stimulation results in increased cyclic-AMP (cAMP) levels, which reduces the toxic effects of amyloid-beta 1-42, a hallmark of Alzheimer's disease.

SourceJohns Hopkins Medicine·JournalEuropean Journal of Neuroscience·DateNov 21, 2005